Cargando…

Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice

Circulating transthyretin (TTR) is a critical determinant of plasma retinol-binding protein 4 (RBP4) levels. Elevated RBP4 levels cause insulin resistance, and the lowering of RBP4 levels improves glucose homeostasis. Since lowering TTR levels increases renal clearance of RBP4, we determined whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zemany, Laura, Bhanot, Sanjay, Peroni, Odile D., Murray, Susan F., Moraes-Vieira, Pedro M., Castoldi, Angela, Manchem, Prasad, Guo, Shuling, Monia, Brett P., Kahn, Barbara B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407860/ https://www.ncbi.nlm.nih.gov/pubmed/25524914 http://dx.doi.org/10.2337/db14-0970

Ejemplares similares

Peripheral Reduction of FGFR4 with Antisense Oligonucleotides Increases Metabolic Rate and Lowers Adiposity in Diet-Induced Obese Mice
por: Yu, Xing Xian, et al.
Publicado: (2013)

Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
por: Viney, Nicholas J., et al.
Publicado: (2020)

Antigen Presentation and T-Cell Activation Are Critical for RBP4-Induced Insulin Resistance
por: Moraes-Vieira, Pedro M., et al.
Publicado: (2016)

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)

Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations
por: Huang, Lulu, et al.
Publicado: (2019)

Hepatocytes Are the Principal Source of Circulating RBP4 in Mice
por: Thompson, Spencer J., et al.
Publicado: (2017)

A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
por: Millns, Helen, et al.
Publicado: (2015)

Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
por: Tasfaout, Hichem, et al.
Publicado: (2017)

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
por: Gales, Luís
Publicado: (2019)

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
por: Prakash, Thazha P., et al.
Publicado: (2014)

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
por: Crooke, Stanley T., et al.
Publicado: (2017)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells
por: Wacheck, V, et al.
Publicado: (2003)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2021)

Targeted delivery of antisense oligonucleotides to pancreatic β-cells
por: Ämmälä, C., et al.
Publicado: (2018)

A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity
por: Ochaba, Joseph, et al.
Publicado: (2019)

Antisense oligonucleotide‐mediated knockdown of Mpzl3 attenuates the negative metabolic effects of diet‐induced obesity in mice
por: Worley, Beth L., et al.
Publicado: (2021)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Mannosylated Chitosan Nanoparticles for Delivery of Antisense Oligonucleotides for Macrophage Targeting
por: Shilakari Asthana, Gyati, et al.
Publicado: (2014)

Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice
por: Krüger, Janine, et al.
Publicado: (2013)

Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide
por: Grossman, Tamar R., et al.
Publicado: (2017)

In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis
por: Bezerra, Filipa, et al.
Publicado: (2021)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
por: McPhillips, F, et al.
Publicado: (2001)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3eje27cavfh9pqrqeum8evi39h